Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
Y-mAbs Therapeutics, Inc. (YMAB) shares rallied 9.5% in the last trading session to close at $14.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 35.9% gain over the past four weeks.
The stock rallied as optimism about the drug/biotech sector’s growth in 2024 rose.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -766.7%. Revenues are expected to be $21.72 million, down 30.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Y-mAbs Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on YMAB going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Y-mAbs Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Moderna (MRNA), finished the last trading session 1.8% higher at $89. MRNA has returned -17.5% over the past month.
For Moderna , the consensus EPS estimate for the upcoming report has changed +6.3% over the past month to -$0.82. This represents a change of -122.7% from what the company reported a year ago. Moderna currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Y-mAbs Therapeutics, Inc. (YMAB) : Free Stock Analysis Report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
